Tirzepatide’s cardiovascular effects in clinical practice
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
By
Kathryn Wighton
August 28, 2026
Clinical Scorecard: Tirzepatide’s cardiovascular effects in clinical practice
At a Glance
Category Detail
Condition Type 2 diabetes with established atherosclerotic cardiovascular disease Key Mechanisms Comparison of cardiovascular outcomes between tirzepatide and sitagliptin Target Population Patients aged 40 years or older with type 2 diabetes and established atherosclerotic cardiovascular disease Care Setting Population-based cohort study
Key Highlights
Tirzepatide associated with lower 1-year risk of major adverse cardiovascular events (MACE) compared to sitagliptin. Weighted MACE risk: 3% with tirzepatide vs. 4% with sitagliptin. Lower risks of myocardial infarction and all-cause mortality with tirzepatide. Fewer infection-related hospital admissions with tirzepatide. Study limited by short follow-up and potential residual confounding. Guideline-Based Recommendations
Diagnosis
Patients should have documented previous myocardial infarction, ischemic stroke, or arterial disease. Management
Consider tirzepatide for patients with type 2 diabetes and established cardiovascular disease. Monitoring & Follow-up
Monitor for major adverse cardiovascular events during treatment. Risks
Be aware of potential residual confounding affecting mortality findings. Patient & Prescribing Data
Patients aged 40 years or older with type 2 diabetes and established atherosclerotic cardiovascular disease.
Tirzepatide may provide cardiovascular benefits compared to sitagliptin.
Clinical Best Practices
Utilize overlap weighting to balance baseline characteristics in treatment comparisons. Assess absolute risk differences and number needed to treat for clinical decision-making. Related Resources & Content
